Durvalumab showed significant improvements in event-free survival and overall survival in muscle-invasive bladder cancer patients compared to chemotherapy alone. The phase 3 NIAGARA study involved ...

TAR-200 monotherapy achieved an 83.5% complete response rate in BCG-unresponsive high-risk NMIBC patients, with a high insertion success rate of 98.8%. The treatment was well tolerated, with most ...

The trial targets intermediate-risk non-muscle invasive bladder cancer, focusing on superficial stage A, primarily low-grade tumors. Cretostimogene grenadenorepvec is compared to surveillance in a ...

Early and aggressive treatment strategies are crucial for improving outcomes in high-risk metastatic castration-sensitive prostate cancer. Combining androgen deprivation therapy with novel hormonal ...